Pfizer says Sutent breast cancer trials fail

LOS ANGELES, March 11 (Reuters) – Pfizer Inc (PFE.N) said on Thursday that two late-stage breast cancer trials involving its cancer drug Sutent failed to meet their goals and it has stopped a pivotal lung cancer trial of experimental drug figitumumab.

Pfizer said outside monitors concluded that the Phase 3 trial of figitumumab in patients with previously treated advanced non-small cell lung cancer was unlikely to show that the drug was effective.

The world’s largest drugmaker is seeking new medicines as patents begin to expire on many of its top-selling products.

Read More :Pfizer says Sutent breast cancer trials fail

Related Youtube Video

[!] Report Abuse

Processing your request, Please wait....

Report as:	Invalid Contents Other
Write in Words: (Optional)

Short URL:http://www.usposttoday.com/?p=1564

Posted by uspost on Mar 13 2010. Filed under Health. You can follow any responses to this entry through the RSS 2.0. Both comments and pings are currently closed.